Oncology Peer Review On-The-Go: Kami Maddocks, MD, on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL
CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.
CancerNetwork® spoke with Kami Maddocks, MD, an associate professor of clinical internal medicine in the Division of Hematology at The Ohio State University Wexner Medical Center, about CD19-directed agents, avoiding rechallenging with rituximab (Rituxan), and outcomes with second-line therapy for transplant-ineligible patients with diffuse large B-cell lymphoma.
Visit cancernetwork.com to check out the first episode of this 3-part series here.
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous System
Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Highlighting Insights From the Marginal Zone Lymphoma Workshop
Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.
